Abstract
International trade policy initiatives, including trade negotiations and regulatory dialogues, have a rather significant impact on the industry. This is particularly the case for the pharmaceutical sector, which is a highly regulated sector. Non-tariff barriers (NTBs) to trade have a negative effect on generic and biosimilar medicine exporters as they often create an advantage for local companies. To aim at their removal, several actions can be taken by governments both at bilateral level or with the World Trade Organization in the context of its dispute resolution procedures. NTBs can also be addressed in the context of trade agreements or bilateral and plurilateral regulatory dialogues. Regulatory cooperation in trade agreements can produce very positive results for patients, industry and regulators, as the Transatlantic Trade and Investment Partnership Agreement (TTIP) demonstrate.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
